Form 4: Monogram Orthopaedics CFO Noel Knape Acquires 25,000 Stock Options

Noel Knape, CFO of Monogram Orthopaedics, reports the acquisition of 25,000 stock options on April 24, 2024.

Summary

• Noel Knape, the Chief Financial Officer of Monogram Orthopaedics Inc. (MGRM), filed a Form 4 on April 26, 2024.
• The form reports a transaction that occurred on April 24, 2024, where Knape acquired 25,000 stock options.
• These options were issued under the company's 2019 Stock Option and Grant Plan with an exercise price of $2.33.
• 25% of the shares underlying the options will vest on April 24, 2025, and the remaining 75% will vest in 12 equal 6-month installments over the next six years, becoming fully vested on April 24, 2030, contingent upon continued service with the company.
• Following the reported transaction, Knape directly owns 75,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and signals confidence in the company's future, but it's not a major event.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's long-term success.

Future Outlook

The vesting schedule indicates a long-term commitment from the CFO to the company, as the options vest over a six-year period.

Industry Context

Stock option grants are a common practice in the industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the orthopaedics industry, similar to companies like Stryker, Zimmer Biomet, and Smith & Nephew.
• The vesting schedule of six years is within the typical range for such grants, aligning with long-term performance goals.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with the company's long-term success.

Key Dates